Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry

Author:

Baudy Andreas R.123ORCID,Otieno Monicah A.453,Hewitt Philip678,Gan Jinping9103ORCID,Roth Adrian111213,Keller Douglas143ORCID,Sura Radhakrishna15163,Van Vleet Terry R.15163,Proctor William R.17183

Affiliation:

1. Merck & Co., Inc.

2. Kenilworth

3. USA

4. Janssen Pharmaceutical Research and Development

5. Spring House

6. Merck KGaA

7. Darmstadt

8. Germany

9. Bristol-Myers Squibb

10. New York City

11. Roche Innovation Centre

12. Basel

13. Switzerland

14. Sanofi, Bridgewater

15. AbbVie, Inc.

16. Chicago

17. Genentech, Inc.

18. South San Francisco

Abstract

This pharmaceutical industry guidance based on a 3-staged benchmarking strategy aims to help MPS developers and end users identify what could be the most valuable models for safety risk assessment, as well as provide an overview of contexts of use.

Publisher

Royal Society of Chemistry (RSC)

Subject

Biomedical Engineering,General Chemistry,Biochemistry,Bioengineering

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3